Coronavirus (COVID-19)
Learn more
Stereotactic Body Radiation Therapy with Consolidation Durvalumab in High-Risk Early-Stage Non-Small Cell Lung Cancer – A Phase II Single-Arm Trial
The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center.
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209